ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0359

SpA Disk©: A New Tool to Monitor the QoL of Spondyloarthritis Patients
Abstract Number: 0783

Spatial Reconstruction of Interstitial Lung Disease
Abstract Number: 0832

Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs
Abstract Number: 2544

Spatial Transcriptomics Suggests Synovial Macrophage Niches Are Sexually Dimorphic in a Mouse Inflammatory Arthritis Model
Abstract Number: 0985

Specific Causes for Hospitalization in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review
Abstract Number: 2086

Specific Transcriptomic Profile Associated with Disease Activity in Muscle Biopsies from Patients with Sarcoid Myopathy
Abstract Number: 0060

Spectral Cytometry Shows Increased CD56hi NK Cells and New HLA-DR+CD56+ Phenotypes in RA
Abstract Number: 0230

Spine and Sacroiliac Joint Involvement in Newly Diagnosed Patients with Inflammatory Bowel Disease – Clinical and MRI Findings from a Population-Based Cohort Study
Abstract Number: 0235

Spine Structural Lesions in Ankylosing Spondylitis: Comparison Between Radiographic (RASSS) and Opportunistic Thoraco-abdomino-pelvic CT Assessment
Abstract Number: 0063

Splicing into Action:Investigating the Role of Alternative Splicing in Rheumatoid Arthritis Neutrophils
Abstract Number: 0319

Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Abstract Number: 1828

SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling
Abstract Number: 0071

Stage-Specific Roles of Interleukin-23/Interleukin-17 Axis and Type 1 Regulatory T Cells Dynamics in Axial Spondyloarthritis
Abstract Number: 1766

STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility
Abstract Number: 0986

State-and-County-Level Social Vulnerability Index and Trends in Systemic Lupus Erythematosus-Related Mortality in the U.S

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].